- Home
- Publications
- Publication Search
- Publication Details
Title
Chronic Lymphocytic Leukemia: An Update on Biology and Treatment
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 13, Issue 5, Pages 379-385
Publisher
Springer Nature
Online
2011-07-19
DOI
10.1007/s11912-011-0188-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells
- (2011) J. C. Allen et al. BLOOD
- The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
- (2010) M. Suljagic et al. BLOOD
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154
- (2010) W G Wierda et al. LEUKEMIA
- Antigens in chronic lymphocytic leukemia—Implications for cell origin and leukemogenesis
- (2010) Anders Rosén et al. SEMINARS IN CANCER BIOLOGY
- First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
- (2009) B. F. Eichhorst et al. BLOOD
- Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
- (2009) Y. Xu et al. BLOOD
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
- (2009) R. Lapalombella et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
- (2009) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
- (2008) Thomas Decker et al. ANNALS OF HEMATOLOGY
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro
- (2008) Lilian Amrein et al. BRITISH JOURNAL OF HAEMATOLOGY
- Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
- (2008) Leslie A. Andritsos et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells
- (2008) S Gobessi et al. LEUKEMIA
- Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination
- (2008) Anna Åleskog et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started